Rep. Lisa C. McClain Sells AstraZeneca PLC (NASDAQ:AZN) Shares

Representative Lisa C. McClain (R-Michigan) recently sold shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in AstraZeneca stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

AstraZeneca Stock Performance

NASDAQ:AZN opened at $93.24 on Wednesday. The company has a market cap of $289.18 billion, a P/E ratio of 35.05, a P/E/G ratio of 1.52 and a beta of 0.34. The firm’s 50 day moving average is $83.58 and its two-hundred day moving average is $77.23. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $93.41. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Thursday, November 6th. The company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. During the same period in the prior year, the firm posted $2.08 EPS. The business’s revenue for the quarter was up 12.0% on a year-over-year basis. Analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Brighton Jones LLC increased its stake in AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after buying an additional 2,789 shares during the period. Venturi Wealth Management LLC grew its stake in shares of AstraZeneca by 4.3% during the first quarter. Venturi Wealth Management LLC now owns 25,440 shares of the company’s stock valued at $1,870,000 after acquiring an additional 1,044 shares in the last quarter. Wedbush Securities Inc. increased its position in shares of AstraZeneca by 36.1% during the first quarter. Wedbush Securities Inc. now owns 8,165 shares of the company’s stock worth $600,000 after acquiring an additional 2,166 shares during the last quarter. AE Wealth Management LLC increased its position in shares of AstraZeneca by 3.0% during the first quarter. AE Wealth Management LLC now owns 9,681 shares of the company’s stock worth $712,000 after acquiring an additional 285 shares during the last quarter. Finally, Pinnacle Associates Ltd. lifted its stake in shares of AstraZeneca by 4.1% in the first quarter. Pinnacle Associates Ltd. now owns 31,183 shares of the company’s stock worth $2,292,000 after acquiring an additional 1,225 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on AZN shares. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Finally, Jefferies Financial Group began coverage on shares of AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating on the stock. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and an average target price of $86.00.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.